EGETIS THERAPEUTICS

Corporate presentation

April 2022

An integrated orphan drug company, focusing on late-stage development for commercialization

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Egetis Therapeutics AB (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information"). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not intended for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any other jurisdiction where such distribution would be unlawful. This presentation is not a prospectus or similar document and it has not been approved, registered or reviewed by the Swedish Financial Supervisory Authority nor any governmental authority or stock exchange in any jurisdiction.

The Information has been prepared by the Company and is intended to present background information on the Company, its business and the industry in which it operates. The Information contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any investment activity. The Company shall not have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the Information or otherwise arising in connection with this presentation.

By accessing this Information, you represent that such access does not violate any registration requirements or other legal restrictions in the jurisdiction in which you reside or conduct business. It is especially noted that the Information may not be accessed by persons within the United States or "U.S. Persons" (as defined in Regulation S under the Securities Act of 1933, as amended (the "Securities Act") unless they are qualified institutional buyers "QIBs" as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. Further, the Information may not be accessed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"), a "qualified investors" falling within Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA"), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a "Relevant Person"). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. As a result, you are cautioned not to place undue reliance on such forward-looking statements.

No representation, warranty or undertaking, express or implied, is made by or on behalf of the Company as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaim any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Agenda

1. An integrated orphan drug company, focusing on late-stage development for commercialization
2. Emcitate®
    - Clinical development program
    - Commercial opportunity
3. Aladote®
    - Clinical development program
    - Commercial opportunity
4. The orphan drug segment and path to market
5. Summary

A. Appendix

1.

An integrated orphan drug company, focusing on late-stage development for commercialization

An integrated orphan drug company, focusing on late-stage development for commercialization

1. Dedicated orphan drug development company with two late-stage orphan drug assets: **Emcitate®** and **Aladote®**
2. Target **MAA/NDA** submissions for **Emcitate** in **2023** and for **Aladote** in **2024/2025**
3. Highly attractive **orphan drug segment** with potential **>$1Bn annual sales opportunity**
4. Plan to **launch** through niche inhouse commercial organization in the EU and US
5. Combined core expertise in **late-stage orphan clinical development, registration and commercialization** with experience from:

Listed on NASDAQ Stockholm (EGTX)

HQ in Stockholm, Sweden

Orphan drug segment – a highly attractive opportunity

Shorter clinical development time[1]

Phase II to launch Average # of years



Higher attainable prices[2]

Mean cost per patient and year (USDk)



Higher probability of success[3]

Phase III to approval

POS in metabolic/endocrinology indications



Fewer patients for clinical trials[4]

Patients per trial



Orphan drugs attractive returns[5]



Source: (1) Orphan drug development: an economically viable strategy for biopharma R&D, Meekings, Williams & Arrowsmith, 2012; (2) EvaluatePharma; (3) Estimation of clinical trial success rates and related parameters, C. Wong, K. Siah, A. Lo, Biostatistics, 2019; (4) BioMed Central; (5) EvaluatePharma Orphan Drug Report 2013 Note: Orphan Drugs: Populations of less than 5/10,000 inhabitants in the EU or <200,000 inhabitants in the US

Pipeline overview

Planned Emcitate EU and US filings in 2023



Two highly promising orphan drug candidates

Emcitate® – *Therapy for genetic disturbance in thyroid hormone signaling with life-long severe disability*

- Lead candidate for addressing MCT8 deficiency which affects ~1:70,000 males, a condition with high unmet medical need and no available treatment. No competing sponsored products in clinical development
- Obtained Orphan drug designation in the EU and US 2017 and 2019, respectively. **US Rare Pediatric Disease Designation received in Nov 2020**, eligible for Priority Review Voucher. Fast track designation granted by FDA in Oct 2021
- Triac Trial I (Phase IIb) completed with **significant** and **clinically** relevant effects on **T3 levels** and the manifestations of **chronic thyrotoxicosis**
- Real-world data published in **Oct 2021 confirms long-term efficacy and safety** of Emcitate® in MCT8 deficiency patients
- Intend to **submit MAA** to EMA based on existing clinical data in **H1 2023**
- Intend to **submit NDA** in **mid 2023** based on treatment **effect on T3 levels** and the manifestations of **chronic thyrotoxicosis** in MCT8-deficiency. A placebo-controlled study in 16 treated patients will be conducted to verify the results on T3
- Triac Trial II fully recruited; to establish the effects of early intervention on neurocognitive development, previously seen in the Triac Trial I. Results are expected in Q1 2024
- More than 140 patients are being **treated** with Emcitate on a **named patient basis**, following individual regulatory approvals from national regulatory agencies

Aladote® – *Prevents acute liver injury caused by paracetamol/acetaminophen poisoning*

- Paracetamol poisoning is one of the most common overdoses with >175,000 hospital admissions globally per annum
- No adequate treatment exists for increased risk patients
- Orphan drug designation (ODD) granted in 2019 in the US
- Ongoing dialogue with EMA on the appropriate scope of the indication for an ODD in the EU
- Successful results from Phase Ib/IIa study in paracetamol overdosed patients
- Pivotal Phase IIb/III study planned for marketing authorization application in both US and EU, targeting study start in 2022
- No competing products in clinical development

2.

Emcitate® - clinical development program

MCT8 deficiency: a detrimental condition with significant unmet medical need

What is MCT8 deficiency?

- Genetic disorder resulting in impaired thyroid hormone trafficking across cellular membranes
- MCT8 is one of the key thyroid hormone transporters in the body
- Mutation located on the X chromosome, affecting only males
- Estimated prevalence of 1:70,000 males

Patients with MCT8 Deficiency[1)]

What does it mean?

- Absence of a functional MCT8 protein means that thyroid hormone is not able to pass into cells dependent on MCT8 and importantly cross the blood-brain-barrier, resulting in too low or no thyroid hormone levels in such tissues, including the brain
- Disrupted feedback loop mechanism results in a compensatory increase in circulating thyroid hormone
- Tissues depending on other transporters than MCT8 for thyroid hormone transport will suffer from too high thyroid hormone levels

- Simultaneous too high and too low thyroid hormone stimulation in different tissues

What are the challenges?

- Patients appear normal at birth with normal weight, length and head circumference with no evident signs of significant thyroid hormone disturbance
- Initial symptoms appear within the first months of life
- Disruption of normal neurodevelopment in childhood resulting in severe intellectual disability
- Most patients never develop autonomy or ability to sit or walk and have limited ability to communicate
- Life-long morbidity from disturbed thyroid hormone pattern, resulting in agitation, cardiovascular symptoms, wasting and impaired life expectancy
- Heavily dependant on caregivers resulting in very high disease burden

How do you manage the disease?

- Currently no therapy available to address the root cause of the disorder
- Standard therapeutic approaches for thyroid dysfunction not effective or suitable
- Easy diagnosis once considered with readily available, low-cost laboratory test
- Large proportion of patients remain undiagnosed with significant delay to diagnosis

- Significant unmet medical need from a humanitarian, health economic and societal perspective

Quick facts from natural history[2]

Median life expectancy:	**35 years**
Median onset of symptoms:	**4 months**
Median age of diagnosis:	**24 months**
Patients surviving into adulthood:	**70%**
Severe intellectual disability:	**100%**
Global delay in myelination:	**100%**
Reduced white matter volume:	**100%**
Neurocognitive development age:	**<12m**
Ability to sit independently:	**8%**
Global hypotonia, hypertonia and persistence of primitive reflexes:	**90%**
Requires tube feeding:	**36%**
Severe underweight:	**75%**
Cardiac arrythmias (PAC):	**76%**
Life long 24-hour care:	**100%**

Note: 1) Picture from Schwarz et al; Clin Endocrinol & Met 2007; 2) Groeneweg et al, Lancet Diabetes & Endocrinology, 2020

Orphan drug candidate

with clear scientific and mechanistic rationale and established safety profile

Difference normal MCT8 and deficiency of MCT8

- Thyroid hormone T3 requires transporters such as MCT8 to enter the target cells

Normal MCT8 ✔

- Functional thyroid gland producing T3
- Functioning production of MCT8

→ T3 cross the cellular membrane and enters the target cell



Mutated MCT8 ✘

- Functional thyroid gland producing T3
- MCT8 deficiency leads to absence or loss of function of MCT8 on the cell surface

→ T3 cannot cross the cellular membrane and fails to enter the target cell



Emcitate (tiratricol) – Addressing the MCT8 deficiency

- Tiratricol is a thyroid hormone analogue with high chemical and structural similarity to T3
- Unlike T3, tiratricol can cross cellular membranes without a functional MCT8 transporter
- Tiratricol can bypass the problem in patients with MCT8 deficiency, enter MCT8 deficient cells and restore thyroid hormone signalling
- Experience from 40 years on the French market in a different indication, owned and controlled by company

Emcitate in action



Without a functioning MCT8, T3 is unable to be transported across the cell membrane to enter the target cell ✘

Emcitate (tiratricol) can enter the cell without MCT8 and restore thyroid hormone signaling ✔

Emcitate® Overview

Lead candidate for addressing MCT8 deficiency, a condition with high unmet medical need and no available treatment

Clinical

- Triac Trial I completed with significant and clinically relevant effects
- **Erasmus Medical Center cohort study confirms long-term efficacy and safety in MCT8 deficiency patients for up to 6 years (Oct 2021)**
- Triac Trial II, early intervention trial in young subjects to establish the effect on the neurocognitive development aspects of the disease, previously seen in the Triac Trial I. Fully recruited early April 2022. Results expected Q1 2024

Regulatory

- Orphan drug designation in EU & US, US Rare Pediatric Disease Designation - **eligible for Priority Review Voucher**
- **Fast track designation** granted by FDA (Oct 2021)
- **Intend to submit MAA to the EMA based on existing clinical data H1 2023**
- US **NDA submission planned mid-2023**: A 30-day, placebo-controlled study in 16 patients will be conducted to verify the results on T3 levels seen in previous clinical trials and publications

Commercial

- Estimated 10k – 15k MCT8 deficiency patients (1:70k males), no sponsor-initiated products in clinical development
- Analogue orphan drugs priced at premium
- **Launched disease awareness initiatives to support diagnosis of MCT8 deficiency**
- More than 140 patients are being treated with Emcitate on a named patient or compassionate use basis, following individual regulatory approvals from national regulatory agencies
- Expected **market exclusivity** is **12y in EU** (ODD 10y, pediatric ext. 2y), **7.5y in US** (ODD 7y, pediatric 0.5y)

Overview of completed Phase IIb – Triac Trial I

Primary objective and results

- Evaluate the efficacy and safety of oral administration of tiratricol in male patients with MCT8 deficiency of all ages
- Highly significant primary outcome - Change in T3 serum concentrations
- Safe and tolerable
- Results published in *The Lancet* 2019

Secondary objective and results

- Change in other thyroid hormone function tests, thyrotoxic symptoms and markers
- Significant and clinically relevant effects observed across secondary endpoints

Description

- An international, single-arm, open-label, Phase II trial
- ClinicalTrials.gov identifier: NCT02060474

# of patients

- 46 MCT8 patients in 9 countries

Timetable

- Initiated in October 2014 (first patient in)
- Completed in June 2018

THE LANCET

Articles

Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial

Stefan Groeneweg, Robin P Peeters, Carla Moran, Athanasia Stoupa, Françoise Auriol, Davide Tonduti, Alice Dicu, Laura Paone, Klara Rozenkova, Jana Malikova, Adri van der Walt, Irenaeus F M de Coo, Anne McGowan, Greta Lyons, Femke K Aarsen, Diana Barca, Ingrid M van Beynum, Marieke M van der Knoop, Jurgen Jansen, Martien Manshande*, Roelineke J Lunsing, Stan Nowak, Carsiaan A den Uil, M Carola Zillikens, Frank E Visser, Paul Vrijmoeth, Marie Claire Y de Wit, Nicole I Wolf, Angelique Zandstra, Gautam Ambegaonkar, Yogen Singh, Yolanda B de Rijke, Marco Medici, Enrico S Bertini, Sylvia Depoorter, Jan Lebl, Marco Cappa, Linda De Meirleir*, Heiko Krude, Dana Craiu, Federica Zibordi, Isabelle Oliver Petit, Michel Polak, Krishna Chatterjee, Theo J Visser*, W Edward Visser

Summary

Background Deficiency of the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) causes severe intellectual and motor disability and high serum tri-iodothyronine (T_3) concentrations (Allan–Herndon–Dudley syndrome). This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected individuals to substantial morbidity and mortality. Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the T_3 analogue Triac (3,3',5-tri-iodothyroacetic acid, or tiratricol), in patients with MCT8 deficiency.

Methods In this investigator-initiated, multicentre, open-label, single-arm, phase 2, pragmatic trial, we investigated the effectiveness and safety of oral Triac in male paediatric and adult patients with MCT8 deficiency in eight countries in Europe and one site in South Africa. Triac was administered in a predefined escalating dose schedule—after the initial dose of once-daily 350 µg Triac, the daily dose was increased progressively in 350 µg increments, with the goal of attaining serum total T_3 concentrations within the target range of 1·4–2·5 nmol/L. We assessed changes in several clinical and biochemical signs of hyperthyroidism between baseline and 12 months of treatment. The prespecified primary endpoint was the change in serum T_3 concentrations from baseline to month 12. The co-primary endpoints were changes in concentrations of serum thyroid-stimulating hormone (TSH), free and total thyroxine (T_4), and total reverse T_3 from baseline to month 12. These analyses were done in patients who received at least one dose of Triac and had at least one post-baseline evaluation of serum throid function. This trial is registered with ClinicalTrials.gov, number NCT02060474.

Findings Between Oct 15, 2014, and June 1, 2017, we screened 50 patients, all of whom were eligible. Of these patients, four (8%) patients decided not to participate because of travel commitments. 46 (92%) patients were therefore enrolled in the trial to receive Triac (median age 7·1 years [range 0·8–66·8]) . 45 (98%) participants received Triac and had at least one follow-up measurement of thyroid function and thus were included in the analyses of the primary endpoints. Of these 45 patients, five did not complete the trial (two patients withdrew [travel burden, severe pre-existing comorbidity], one was lost to follow-up, one developed of Graves disease, and one died of sepsis). Patients required a mean dose of 38·3 µg/kg of bodyweight (range 6·4–84·3) to attain T_3 concentrations within the target range. Serum T_3 concentration decreased from 4·97 nmol/L (SD 1·55) at baseline to 1·82 nmol/L (0·69) at month 12 (mean decrease 3·15 nmol/L, 95% CI 2·68–3·62; p<0·0001), while serum TSH concentrations decreased from 2·91 mU/L (SD 1·68) to 1·02 mU/L (1·14; mean decrease 1·89 mU/L, 1·39–2·39; p<0·0001) and serum free T_4 concentrations decreased from 9·5 pmol/L (SD 2·5) to 3·4 (1·6; mean decrease 6·1 pmol/L (5·4–6·8; p<0·0001). Additionally, serum total T_4 concentrations decreased by 31·6 nmol/L (28·0–35·2; p<0·0001) and reverse T_3 by 0·08 nmol/L (0·05–0·10; p<0·0001). Seven treatment-related adverse events (transiently increased perspiration or irritability) occurred in six (13%) patients. 26 serious adverse events that were considered unrelated to treatment occurred in 18 (39%) patients (mostly hospital admissions because of infections). One patient died from pulmonary sepsis leading to multi-organ failure, which was unrelated to Triac treatment.

Interpretation Key features of peripheral thyrotoxicosis were alleviated in paediatric and adult patients with MCT8 deficiency who were treated with Triac. Triac seems a reasonable treatment strategy to ameliorate the consequences of untreated peripheral thyrotoxicosis in patients with MCT8 deficiency.

Funding Dutch Scientific Organization, Sherman Foundation, NeMO Foundation, Wellcome Trust, UK National Institute for Health Research Cambridge Biomedical Centre, Toulouse University Hospital, and Una Vita Rara ONLUS.

Lancet Diabetes Endocrinol 2019

Published Online July 31, 2019 http://dx.doi.org/10.1016/S2213-8587(19)30155-X

See Online/Comment http://dx.doi.org/10.1016/S2213-8587(19)30217-7

*Dr Manshande died in August, 2018; Prof De Meirleir died in October, 2018; and Prof T J Visser died in March, 2018

Academic Center for Thyroid Diseases (S Groeneweg MD, Prof R P Peeters MD, M Medici MD, Prof T J Visser PhD, W E Visser MD), Sophia Children's Hospital, Division of Paediatric Cardiology (J M van Beynum MD), Sophia Children's Hospital, Department of Paediatric Neurology (I F M de Coo MD, F K Aarsen PhD, M M van der Knoop MSc, M C Y de Wit MD), Department of Cardiology and Intensive Care Medicine (C A den Uil MD), Department of Clinical Chemistry (Prof Y B de Rijke PhD), and Department of Internal Medicine (Prof M C Zillikens MD), Erasmus Medical Centre, Rotterdam, Netherlands; Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK (C Moran MB, A McGowan MD, G Lyons RCN, K Chatterjee FRCP); Paediatric Endocrinology, Diabetology and Gynaecology Department, Necker Children's University Hospital, Imagine Institute, Paris, France (A Stoupa M D, Prof M Polak M D); Department of Paediatric Endocrinology and Genetics, Children's Hospital, Toulouse University Hospital, Toulouse, France

www.thelancet.com/diabetes-endocrinology Published online July 31, 2019 http://dx.doi.org/10.1016/S2213-8587(19)30155-X 1

Source: Groeneweg et al, Lancet D&E 2019;

Consistent, clinically relevant and highly significant results

Reached target level serum T3 in completed Phase IIb trial (Triac Trial I)



Endpoints	Baseline mean *(± SD)*	12 months mean *(± SD)*	Difference in means *(95% CI)*	p-value
Serum T3 (nmol/L)	4.97 (± 1.55)	1.82 (± 0.69)	-3.15 (-3.62, -2.68)	<0.0001
Weight to age (z score)	-2.98 *(± 1.93)*	-2.71 *(± 1.79)*	0.27 *(0.03, 0.50)*	0.025
Resting heart rate (bpm)	112 *(± 23)*	104 *(± 17)*	-9 *(-16, -2)*	0.01
Mean heart rate 24 h (bpm)	102 *(± 14)*	97 *(± 9)*	-5 *(-9, -1)*	0.012
SHBG (nmol/L)	212 *(± 91)*	178 *(± 76)*	-35 *(-55, -15)*	0.0013
Total cholesterol (mmol/L)	3.2 *(± 0.7)*	3.4 *(± 0.7)*	0.2 *(0.0, 0.3)*	0.056
CK (U/L)	108 *(± 90)*	161 *(± 117)*	53*(27, 78)*	<0.0001

Source: Groeneweg et al; Lancet D&E 2019

Indication of positive effect on neurocognitive development

In the youngest patients which is further studied in ongoing Triac Trial II



Source: Groeneweg et al; Lancet D&E 2019

New data confirms long-term efficacy and safety of Emcitate® in MCT8 deficiency patients

Published in October, 2021

ACCEPTED MANUSCRIPT

Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency: a real-life retrospective cohort study

Ferdy S van Geest, Stefan Groeneweg, Erica L T van den Akker, Iuliu Bacos, Diana Barca, Sjoerd A A van den Berg, Enrico Bertini, Doris Brunner, Nicola Brunetti-Pierri, Marco Cappa ... Show more

Author Notes

JCEM THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

- Investigator-initiated real-world cohort study at 33 sites conducted by the Erasmus Medical Center
- Investigated efficacy and safety of Emcitate in 67 patients with MCT8 deficiency
  - Median baseline age of 4.6 years (range: 0.5–66 years) and were treated with tiratricol for up to 6 years, with a median of 2.2 years (range 0.2 – 6.2 years)
  - The primary endpoint in the study was the change in serum T3 concentration from baseline to last-available measurement
  - The pre-specified secondary endpoints were key measurements of clinical complications of chronic peripheral thyrotoxicosis

New patient cohort of equal size to the Triac Trial I

Long term follow up up to >6 years

Triac Trial I
N=46

Triac Trial I patients
Available for long-term monitoring
N=27

New patients
From named patient program
N=40

EMC cohort
Published in JCEM
N=67





New cohort confirms primary endpoint results in Triac Trial I

Fast and durable normalization of T3 values in almost all patients



Consistent, clinically relevant and highly significant results across endpoints

- Data confirm the positive results from previous study, Triac Trial I
- Normalization of T3 in serum corresponds to improvement in thyroid hormone status in end target tissues
- Beneficial effects are maintained or continue to improve over time, up to six years
- Consistent efficacy seen across key clinical and biochemical parameters that were sustainably alleviated in patients with MCT8 deficiency regardless of age

Table 2: Changes from baseline to last visit in predefined outcomes

	Baseline mean (SD)	Last visit mean (SD)	Mean change (95% CI)	P value
Primary outcome				
T3 (nmol/L; n=67)	4.58 (1.11)	1.66 (0.69)	-2.92 (-3.23 to -2.61)	<0.0001
Secondary outcomes				
Anthropometric parameters and heart rate				
Body weight (kg; n=58)	17.8 (12.1)	23.6 (14.5)	5.7 (4.2 to 7.2)	
Weight-for-age Z score (n=58)	-2.81 (1.94)	-2.64 (1.81)	0.17 (-0.18 to 0.53)	0.3263
Δ Weight-for-age – predicted weight-for-age Z score (n=55)	0.07 (1.83)	0.79 (1.92)	0.72 (0.36 to 1.09)	0.0002
Height (cm; n=44)	101 (21)	116 (23)	15 (12 to 19)	
Height-for-age Z score (n=44)	-1.84 (1.77)	-1.92 (1.51)	-0.09 (-0.50 to 0.32)	0.6705
Δ Height-for-age – predicted height-for-age Z score (n=43)	-0.44 (1.38)	0.14 (1.41)	0.58 (0.12 to 1.05)	0.0139
Weight-for-height Z score (n=44)	-2.02 (2.49)	-1.50 (2.44)	0.52 (-0.35 to 1.39)	0.2358
Heart rate (bpm; n=48)	113 (21)	97 (20)	-17 (-24 to -10)	<0.0001
Heart rate-for-age Z score (n=48)	1.59 (0.89)	0.96 (1.01)	-0.64 (- 0.98 to -0.29)	0.0005
Thyroid function tests				
TSH (mU/L; n=62)*	3.32 (2.30)	0.95 (0.73)	-2.38 (-2.98 to -1.77)	<0.0001
Free T4 (pmol/L; n=64)	9.5 (2.3)	3.4 (1.6)	-6.1 (-6.7 to -5.4)	<0.0001
T4 (nmol/L; n=63)	54.2 (11.8)	18.1 (9.8)	-36.1 (-39.5 to -32.7)	<0.0001
Peripheral markers				
Sex hormone-binding globulin (nmol/L; n=48)	245 (99)	209 (92)	-36 (-57 to -16)	0.0008
Creatinine (µmol/L; n=47)	32 (11)	39 (13)	7 (6 to 9)	<0.0001
Creatine kinase (U/L; n=47)*	110 (87)	128 (80)	18 (-8 to 45)	0.2166

All outcomes were assessed in all patients who received Triac treatment longer than the mean time to optimal dose (5.0 months; N=64). Data are mean. Body weight-for-age Z scores were calculated using TNO growth calculator and heart rate-for-age Z scores were calculated using the Boston Z score calculator. Abbreviations: T3=tri-iodothyronine. TSH=thyroid-stimulating hormone. T4=thyroxine. *TSH and creatine kinase concentrations were log-transformed to ensure a normal distribution before paired t tests were done (non-transformed means [SDs] and mean changes [95% CIs] are presented for the sake of interpretability).

Egetis intends to submit MAA for Emcitate® to EMA in H1 2023 based on existing clinical data

Press release issued Dec 13, 2021

- Based on regulatory interactions, Egetis concludes that **available data** from Triac Trial I and recently published long-term data are **sufficient for a Marketing Authorisation Application (MAA) in Europe**
- Having all clinical data required for regulatory submission already at hand **significantly reduces the remaining risk** for Emcitate
- The ongoing Triac Trial II will continue to further establish the effects of early intervention on the neurocognitive development aspects of the disease

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

- *Egetis concludes, based on recent regulatory interactions, that available Triac Trial I data together with recently published long-term data are sufficient for a Marketing Authorisation Application in Europe*
- *Having all clinical data required for regulatory submission already at hand significantly reduces the remaining risk for Emcitate*
- *Revised submission timelines will be communicated as soon as all parts of the regulatory dossier are confirmed*
- *Egetis will host a webcast today at 15:00 CET (9:00am ET)*

Stockholm, Sweden, December 13, 2021 - Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that after a pre-submission meeting held last week with concerned European regulatory agencies (EMA's Rapporteur and Co-Rapporteur), the Company concludes that the clinical data from the Triac Trial I (Groeneweg et al. 2019), together with the data from long-term treatment with Emcitate (tiratricol) for up to six years in 67 patients (van Geest et al. 2021) will be sufficient for a regulatory review of a Marketing Authorisation Application (MAA) to the European Medicines Agency for the treatment of monocarboxylate transporter 8 (MCT8) deficiency. Thus, all clinical data necessary for regulatory submission is already available. The ongoing Triac Trial II will continue to further establish the effects of early intervention on the neurocognitive development aspects of the disease.

"We are delighted with the outcome of the pre-submission meeting, giving us a clear path to our MAA submission, and subsequent regulatory review, based on existing clinical data. Having all clinical data required for regulatory submission already at hand significantly reduces the remaining risk for Emcitate and could also potentially enable an earlier submission in Europe than we had previously expected. This is a substantial opportunity for us and the European patients suffering from MCT8 deficiency. In parallel, as part of our efforts to make Emcitate available as soon as possible, we continue our dialogues with regulatory authorities in other jurisdictions to obtain their views on the available clinical data and its implications for regulatory submissions" said Nicklas Westerholm, CEO, Egetis Therapeutics.

Treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval in the US – NDA targeted in mid 2023

Press release issued Jan 18, 2022

- FDA acknowledges that a treatment effect on T3 levels and the manifestations of chronic thyrotoxicosis in MCT8-deficiency could provide a basis **for marketing approval** also in the US.
- A small, 30-day, placebo-controlled study in 16 treated patients, to be identified primarily through our existing named patient program, will be conducted to **verify the results on T3** levels seen in previous clinical trials and publications in a randomized **controlled** setting.
- An **NDA** in the US is targeted to be submitted in **mid 2023** under the Fast Track Designation.
- A major step towards marketing authorization and increases the likelihood of success for *Emcitate* and the probability to receive a US Rare Pediatric Disease **Priority Review Voucher (PRV)**.

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

- *Emcitate® (tiratricol) is the first potential treatment of MCT8 deficiency, a rare genetic disease with high unmet medical need and no available treatment*
- *In recent positive regulatory interactions, FDA acknowledges that a treatment effect on T3 levels and the manifestations of chronic thyrotoxicosis in MCT8-deficiency could provide a basis for marketing approval also in the US.*
- *An NDA in the US is targeted to be submitted in mid-2023 under the Fast Track Designation.*
- *A small, 30-day, placebo-controlled study in 16 treated patients, to be identified through the existing named patient program, will be conducted to verify the results on T3 levels seen in previous clinical trials and publications in a randomized controlled setting*
- *This is a major step towards a marketing application and increases the likelihood of success for Emcitate and the probability for Egetis to receive a US Rare Pediatric Disease Priority Review Voucher (PRV).*
- *Egetis will host a webcast today at 15:00 CET (9:00am ET)*

Stockholm, Sweden, January 18, 2022 - Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) (the "Company") today announced that in recent regulatory interactions, the US Food and Drug Administration (FDA) acknowledges that demonstrating a treatment effect on thyroid hormone T3 levels and the manifestations of chronic thyrotoxicosis could provide a basis for marketing approval also in the US. Consequently, the Company now has an aligned regulatory strategy for EU and US. The Company intends to submit a New Drug Application (NDA) in the US for Emcitate® (tiratricol) for the treatment of monocarboxylate transporter 8 (MCT8) deficiency in mid-2023 under the Fast Track Designation granted by the FDA in October 2021. This follows the announcement in December 2021 of intention to submit the Marketing Authorisation Application (MAA) for Emcitate to the European Medicines Agency (EMA) based on existing clinical data on the manifestations of chronic thyrotoxicosis in MCT8 deficiency.

Controlled Study - design

Primary endpoint: Serum T3 levels, measured as the proportion of patients meeting T3 ≥ULN within the randomized treatment period*



* ULN: Upper Limit of Normal

** Randomized treatment period end after 30 days or when rescue criterion (T3 ≥ULN) is met, whichever comes first

Emcitate regulatory pathway to submissions in EU and US

The first potential treatment for MCT8 deficiency, a rare genetic disease with high unmet medical need and no available treatment

Included in MAA in EU

Included in NDA in US

To be added post approval when data available

Triac Trial I

- Completed 2018 (Groeneweg, 2019)
- Open-label, international, multi-centre study
- N= 46

EMC cohort study

- New data 2021 (van Geest, 2021)
- N= 27 from Triac Trial I & N=40 new pts from compassionate use

Natural history

- Retrospective data, 2003 to 2019 (Groeneweg, 2020)
- N= 151

Controlled study

- To be started in 2022
- N= 16
- Pts from named patient/ compassionate use program

Triac Trial II

- Open-label, international, multi-centre study
- Pts ≤ 30 months of age
- Focus on neurocognition
- N= 15-20 planned
- Full 96 weeks data, expected in Q1 2024

Data already available

Triac Trial II fully recruited: to establish effects of early intervention on neurocognitive development

Market approval not dependent on Triac Trial II data

Primary objective	• Confirm findings from Triac Trial I in youngest age group • Improvement in neurocognitive development as measured by GMFM[1] and BSID-III[2] compared to natural history controls
Secondary objective	• Achievement of motor milestones (e.g. hold head, sit independently) • Normalization of thyroid hormone function tests and markers of thyrotoxicosis
Description	• Open label, multi-centre trial in very young children with MCT8 deficiency • International trial with 10 centres in CZ, DE, IT, UK, FR, NL, US • Design discussed and anchored with EMA and FDA • ClinicalTrials.gov identifier: NCT02396459
# of patients	• 15-20 children, 0-30 months of age
Timetable	• First Patient First Visit in Dec 2020, recruitment target met in April 2022 • Results from 96 week read out expected in Q1 2024 and data is expected to be submitted post-approval to regulatory authorities shortly thereafter and available for HTA interactions • Market approval not dependent on Triac Trial II data

Note: (1) Gross motor function measure; (2) Bayley Scales of Infant Development

Emcitate® clinical development timeline

2017

- Licensing of IP, data and know-how within thyroid hormone signaling disorders from Erasmus Medical Centre[1)]
- EU Orphan Drug Designation (ODD)

2018

- Acquisition of all rights and assets relating to Teatrois in France
- Triac Trial I completed
- EMA Protocol Assistance EU

2019

- US Orphan Drug Designation MCT8
- Publication Triac Trial I
- FDA pre-IND meeting
- CTA submissions EU

2020

- CTA approvals in EU
- IND submission
- IND open (SMP)
- US Rare Pediatric Disease Designation (RPD)
- FPFV[2)] pivotal Phase IIb/III early intervention trial

2021

- Fast Track Designation US
- Data published confirms long-term efficacy and safety of Emcitate®

2022/23

- US & EU ODD RTH-β
- Completed recruitment in Triac Trial II
- Conduct 16 pts randomized 30 day study for US NDA
- Filing EU MAA H1 '23 & US NDA mid '23 under Fast Track Designation
- Launch preparations

2024

- EU and US approvals, pricing and launch
- US Priority Review Voucher
- Publication of complete Triac Trial II data (96 weeks)

Note: (1) Erasmus Medical Centre; (2) First patient first visit;

2.

Emcitate® - Commercial opportunity

Estimating 10-15k addressable patients globally

No approved treatment for MCT8 deficiency



MCT8 deficiency prevalence 1:50,000-70,000 males

Male subset of US, EU and RoW approachable population[1]

US, EU and RoW approachable population[1]

MCT8 deficiency epidemiology

- At least one new-born diagnosed per 140,000 live births in the Netherlands in past years, corresponding to 1:70,000 males
- Actual number of patients could be higher:
  - Screening study suggests prevalence of 1:50,000 males[2]
  - Once treatment is available, more patients tend to be diagnosed

Note: 1) RoW approachable population, e.g. UK, Australia, Canada, Japan, Switzerland, South Korea and Turkey, 2) Visser et al, Clinical Endocrinology 2012

Emcitate®– alleviating patient and societal burden

Aiming to provide value for both patients and society

MCT8 deficiency is a detrimental condition with significant unmet medical need and no approved therapy

Patients

- Median life-expectancy of MCT8 patients is 35 years[1]
- Patients underweight for age or without ability to hold head have an even increased risk of premature death.

Society

- All MCT8 patients have significant neurocognitive disability from early childhood and typically require constant, life-long supportive care
- A recent study in a condition with similar severity (SMA) estimated total healthcare cost (excluding treatment cost) to USD 138k per patient and year[2]

Emcitate holds potential to become the **first approved therapy** to address the root cause of MCT8 deficiency, restore thyroid hormone signaling and thereby **prevent disease progression**, alleviate symptoms and **prolong lives**

Source: (1) Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study, Groeneweg et al, The Lancet, 2012; (2) Economic burden of spinal muscular atrophy in the United States: a contemporary assessment, Droege et al, Journal of Medical Economics, 2020;

Supporting diagnosis through disease awareness initiatives

MCT8 deficiency awareness and educational activities launched through various channels

- Disease awareness and educational efforts aim to
  - increase number of physicians who understand how to diagnose and manage MCT8 deficiency
  - speed up diagnosis
- Collaborating with patient advocacy groups and KOLs
- Exhibit at scientific/medical conferences 2022:
  - *European Paediatric Neurology Society*, April, Glasgow
  - *European Thyroid Association*, Sept, Brussels
  - *European Society of Pediatric Endocrinology*, Sept, Rome
- Several channels for efficient reach
  - mct8deficiency.com
  - Mailings
  - Social media
  - Publications



Emcitate supplied globally on a named patient basis

The named patient use (NPU) confirms the significant unmet medical need in MCT8 deficiency and the view of Emcitate's potential to address it

- NPU and compassionate use programs
  - mechanisms to allow early access to a medicine prior to regulatory marketing approval
  - granted to pharmaceuticals under development for situations with high unmet medical needs and where no available treatment alternatives exist or are suitable
- Emcitate is being supplied on a named patient basis, following individual approval from the national medicines agencies, to
  - more than 140 patients
  - in over 25 countries



Analogue orphan drugs priced at premium

Rapid market penetration with considerable sales already 3rd year in market

- Payers in general accept higher prices for orphan drugs compared to traditional drugs and especially if they;
  - Address an ultra **rare** disease, e.g. prevalence less than 1:50,000 people
  - Target a **severe** disease, i.e. life threatening/debilitating
  - Provide **health gain**, rather than just condition stabilization
- Emcitate fulfills these criteria, no other drugs available or being developed for MCT8 deficiency

Analogue orphan drugs

	Vimizim® *Recombinant enzyme*	**Kalydeco®** *Small molecule*	**Spinraza®** *Antisense oligonucleotide*	**Brineura®** *Recombinant enzyme*
Disease	MPS IVA	CF with specific mutations	SMA	CLN2
Rarity - less than 1:50,000 people	✓	✓	✓	✓
Severity – life threatening/debilitating	✓	✓	✓	✓
Health gain	✓	✓	✓	✓
Global annual treatment cost	> $400k	> $250k	> $350k	> $600k
Year of 1st approval	2011	2012	2016	2017
Global sales 3rd year in market	$354mn	$464mn	$1.7bn	$110m
Global sales 2020	$544mn	$803mn	$2.1bn	$110m

FDA granted Rare Pediatric Disease designation to Emcitate®

US Rare Pediatric Disease Priority Review Voucher (PRV) provides a ~$100m opportunity

Overview PRV

- The FDA grants Rare Pediatric Disease designation (RPD) to therapies for serious or life-threatening diseases affecting fewer than 200,000 people in the USA.
- PRV program recently prolonged until FY 2026
- Sponsors holding a RPD can apply to receive a US Rare Pediatric Disease Priority Review Voucher (PRV) up on approval.
- Provides accelerated FDA review of a new drug application for another drug candidate, in any indication, shortening time to market in the US.
- The voucher may be sold or transferred to another sponsor.
- By end 2019 22 PRVs for rare pediatric diseases had been awarded by FDA, 12 were sold with individual voucher sale prices ranging from $67m to $350m.

Examples of PRVs sold

Seller	Buyer	Value	Year
Bavarian Nordics	Undisclosed	$95M	2019
SOBI	AstraZeneca	$95M	2019
Bayer Healthcare	argenx	$100M	2020
Lumos Pharma	Merck	$100M	2020
Sarepta Therapeutics	Gilead	$125M	2020
Albireo	Undisclosed	$105M	2021
BioMarin	Undisclosed	$110M	2022

Under the terms of the acquisition of RTT in Q3 2020, 50% of the potential net proceeds from a sale of a PRV related to Emcitate should be paid as an earnout to the sellers of RTT

3.

Aladote® - clinical development program

Paracetamol/acetaminophen poisoning

– no adequate treatment for increased-risk patients

What is paracetamol/ acetaminophen poisoning?

- Minimum toxic dose of paracetamol/acetaminophen in adults is only **7.5g**
- Risk factors include malnutrition, alcoholism and consumption of other medications
- Paracetamol/acetaminophen poisoning can lead to **acute liver failure, liver transplant** or **death**

How many does it affect?

- **19 billion** units of paracetamol /acetaminophen packages are sold in the US alone every year
- **>175,000 patients hospitalised globally per annum** driven by 89,000 cases/year of paracetamol overdose in the US and 105,000 cases/year in the UK (~ 50% hospitalised)
- ~50% of paracetamol overdose cases are unintentional

Why is current treatment inadequate?

- Efficacy of current NAC (N-acetylcysteine) treatment decreases with time
- Approximately **25% of patients are late arrivals** to hospitals (>8h) – late arrivals are **at increased risk**
- There is **no effective treatment option for patients at increased risk**

A new standard of care is needed

- **Aladote®** aims to become **a new standard of care** for patients with increased risk for liver injury in combination with NAC

Orphan drug candidate

with clear scientific and mechanistic rationale

Early presenters (<8h)
NAC treatment effective against liver injury

- Liver glutathione (GSH) replenished by NAC, toxic NAPQI metabolite excreted as GSH conjugate



- In most cases NAC effectively prevents liver injury i.e. limited need for Aladote®



Late presenters (>8h) are at increased-risk for liver injury
NAC treatment + Aladote® to prevent liver injury

- **Under NAC treatment alone** liver GSH stores depleted by the toxic NAPQI metabolite -> **oxidative stress, mitochondrial dysfunction and liver injury (necrosis)**





- **Aladote®** (calmangafodipir) prevents ROS and RNS formation, restores mitochondrial energy production and **prevents liver injury**

Source: Akakpo et al. 2020, Burke et al. 2010.

Reactive nitrogen species (RNS), Reactive Oxygene Species (ROS)

Overview of completed Phase Ib/IIa

Primary objective and results	• Met primary endpoint of safety tolerability in the combination of Aladote® and NAC • Results presented at the 58th Annual Meeting of the Society of Toxicology, EASL ILC in April, Vienna and published in Lancet's journal EBioMedicine in 2019 • Presented at, American College of Medical Toxicology (ACMT) and Society of Toxicology (SOT), as novel emerging treatments for acetaminophen/ paracetamol toxicity in 2021
Secondary objectives and results	• Measurements of Alanine transaminase (ALT), international normalised ratio (INR), keratin-18, caspase-cleaved keratin-18 (ccK18) and microRNA-122 (mir122) and glutamate dehydrogenase (GLDH) indicates that Aladote® reduce liver injury
Description	• An open label, rising-dose, randomized study exploring safety and tolerability of Aladote® co-treatment with NAC • ClinicalTrials.gov identifier: NCT03177395
# of patients	• Single ascending dose study in 3 dosing cohorts of 8 patients (N=24) as add-on to NAC regime
Timetable	• Initiated in June 2017 (first patient in) • Completed in September 2018


EBioMedicine 46 (2019) 423–430

Contents lists available at ScienceDirect

EBioMedicine

journal homepage: www.ebiomedicine.com

EBioMedicine
Published by THE LANCET

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)

Emma E. Morrison [a], Katherine Oatey [b], Bernadette Gallagher [c], Julia Grahamslaw [c], Rachel O'Brien [c], Polly Black [c], Wilna Oosthuyzen [d], Robert J. Lee [b], Christopher J. Weir [b], Dennis Henriksen [d], James W. Dear [a,*], On behalf of the POP Trial Investigators [1]



Positive proof-of-principle Phase Ib/IIa results

Indicates that Aladote may reduce liver injury

Safety & tolerability

Event	NAC alone	NAC + 2 µmol/kg Aladote	NAC + 5 µmol/kg Aladote	NAC + 10 µmol/kg Aladote
Any AE	6 (100%)	6 (100%)	6 (100%)	6 (100%)
Any SAE	2 (33%)	4 (67%)	2 (33%)	3 (50%)
SAE Starting within 7 days	1 (17%)	1 (17%)	1 (17%)	2 (33%)

- Met primary endpoint of safety tolerability in the combination of Aladote® and NAC
- No AE or SAE probably or definitely related to Aladote®

Liver injury – ALT[1] pre-defined secondary outcome

Event	NAC alone	NAC + 2 µmol/kg Aladote	NAC + 5 µmol/kg Aladote	NAC + 10 µmol/kg Aladote
50% ALT increase	2 (33%)	0 (0%)	0 (0%)	1 (17%)
100% ALT increase	1 (17%)	0 (0%)	0 (0%)	1 (17%)
ALT >100 U/L at 10 hours	2 (33%)	0 (0%)	0 (0%)	0 (0%)
ALT >100 U/L at 20 hours	2 (33%)	0 (0%)	0 (0%)	0 (0%)

- ALT >100 U/L is the indication to stay in hospital

% of patients needing additional NAC infusions after planned 12h NAC infusion



Note: (1) Alanine transaminase (ALT) is a transaminase enzyme also called alanine aminotransferase (ALAT). ALT is found in plasma and in various body tissues especially the liver's hepatocytes. Serum ALT is commonly measured clinically as part of a diagnostic evaluation of hepatocellular injury, to determine liver health

Aladote® demonstrates consistent results of reduced liver injury as measured by exploratory biomarkers

K18



K18 is a measure of cell death and correlate with peak ALT activity during the hospital stay

ccK18



ccK18, is a measure of cell death and correlate with peak ALT activity during the hospital stay

miR-22



miR-122 is a liver specific early marker (micro-RNA) for acute liver injury which predicts a rise in ALT activity following paracetamol overdose

Pivotal Phase IIb/III study for US/EU regulatory submission

Patient population	• Patients who have overdosed on paracetamol with increased risk of liver damage due to late arrival at hospital (> 8h) who need treatment with NAC
NAC regimen	• Approved 21 hours NAC regimen
Treatment groups	• 4 groups in combination with NAC: Aladote® high dose; Aladote® middle dose; Aladote® low dose; Placebo
Initiation of active treatment	• IV (bolus) as soon as possible after randomization and after starting NAC treatment (but no later than 4 hours after starting NAC treatment)
Interim analysis	• Interim analysis after 35 patients per treatment group, which includes a futility analysis, dose selection and analysis of continued study size (number of patients)
Study size	• 250 patients planned
Efficacy endpoints	• Primary: Combination of ALT and INR • Number (%) of patients who need extended NAC treatment after 21 hours • Length of hospital stay • Explorative biomarkers: K18, miR-122 and GLDH
Study countries	• EU, UK and USA

Aladote® clinical development timeline



- ✔ Phase Ib/IIa study fully recruited
- ✔ Initial Phase Ib/IIa results
- ✔ Established Scientific Advisory Board
- ✔ Full Phase Ib/IIa results
- ✔ Submission of ODD

- ✔ US ODD granted
- ✔ Results presented at Society of Toxicology, EASL ILC and Lancet EBiomedicine
- ✔ Regulatory interactions with FDA and EMA

- ✔ Design of pivotal study finalized
- ✔ Regulatory interactions FDA, EMA & MHRA

- Orphan Drug Designation EU
- Initiate pivotal Phase IIb/III study
- Interim analysis after 50% of patients included
- Recruitment completed

- Regulatory submissions Europe/US
- Europe/US approval and launch
- Regulatory submissions ROW

Note: (1) Calmangafodipir composition of matter patent expires.

3.

Aladote® - Commercial opportunity

Estimating at least 175k addressable patients globally

Annual number of POD (paracetamol/acetaminophen overdose) cases hospitalized and receiving i.v. antidote (NAC currently the only option)

POD epidemiology

89,000 cases/year of paracetamol overdose in the US and 105,000 cases/year in the UK

- ~50% hospitalized and receive i.v. antidote treatment
- ~25% are late arrivals

Global paracetamol/acetaminophen exposure varies, leading to POD incidence being different between countries

Aladote®– alleviating patient and societal burden

Aiming to provide value for both patients and society

POD is a life threatening condition with remaining medical needs

Patients

- POD (paracetamol/acetaminophen overdose) can lead to acute liver failure, liver transplant or death
- In US and UK together, yearly > 500 deaths due to POD and more people registered for liver transplantation

Society

- In the US the annual cost in 2010 was estimated at > $1bn to treat patients with POD[1]
- The POD Emergency Department and inpatient cost is approximately USD 13-40k[1]
- The average POD inpatient length of stay is 3.1 days with a variance of +4.4 days for the most severe cases[1]
- US liver transplant costs USD 125-473k[1]

With **Aladote**, the ambition is to **reduce hepatic injury** of POD and thereby contribute to **fewer hospitalization days**, **prevent need** for liver transplantation and **increase survival**

Source:; (1) Adapted from: Altyar A. Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA BMJ Open 2015;5;

Analogue antidotes priced at $ 3.5k – 50k

National emergency hospital stocking guidelines - opportunity for rapid market penetration

- Various antidotes, e.g. vs. drug overdosing, metal poisoning, snake bites and reversal of anticoagulant treatment effects
- Limit morbidity/mortality when used within appropriate time
- National recommendations for stocking of antidotes at hospitals providing emergency care
  - For getting payer/formulary committee acceptance to be stocked, antidotes are in general priced lower than traditional orphan drugs, despite often having orphan status
  - Getting included provides great opportunity for rapid market penetration
    - Praxbind stocked in 3,200 US hospitals < 3 years from launch
    - Andexxa sales $112mn in US alone second year on market
- Analogue antidotes for comparable settings as Aladote have global average costs of $ 3.5k – 50k per treatment

	Naloxone hydrocloride	Praxbind	Andexxa/Ondexxya	Aladote (target profile)
Year of first approval	1971	2015	2018	NA
Poisoning indication	Opioid toxicity	Reversal of anticoagulant effects of the NOAC dabigatran	Reversal of anticoagulant effects of the factor Xa inhibitors apixaban & rivaroxaban	Paracetamol/ acetaminophen toxicity
Cost per treatment	Low since generic	$ 3.5k – 4.5k	$ 25k – 50k	TBD

Aladote® commercial opportunity

– Addressing unmet needs in antidote market create substantial opportunity

- POD is a life-threatening condition with remaining medical needs
- No effective treatments for high-risk patients, e.g. patients arriving > 8h after ingestion
- No other companies developing drugs for POD
- Opportunity for rapid sales uptake due to national emergency hospital stocking guidelines
- Anologue antidotes priced at $3.5k – 50k

Annual number of POD cases hospitalized and receiving i.v. antidote (NAC currently the only option)



>$350mn annual sales opportunity assuming:

- Global average annual treatment cost per patient: $5k
- Addressable patients: >175,000
- Market penetration: 40%

4.

The orphan drug segment and path to market

Orphan drug segment – a highly attractive opportunity

1. **Orphan drug designation is awarded to products targeting limited disease populations[1]**
2. **More than 7,000 known rare diseases**
3. **Approx. 10% of the general population may be affected by a rare disease**
4. **Substantial unmet medical need for patients, only 5% of rare diseases have an approved therapy**

Development

- Less extensive clinical trials
- Agile and faster development process
- Lower costs
- Lower development risk

Registration

- Free regulatory advice
- Reduced fees
- Expedited review
- Market exclusivity

Market

- No or few competitors
- Highly focused target groups
- Premium pricing

Well-defined patient populations with substantial unmet medical need

Note: (1) Populations of less than 5/10,000 inhabitants in the EU or <200,000 inhabitants in the US

CAGR estimates of total pharmaceutical market vs orphan

The global orphan or rare disease market size was valued at an estimated USD 140 – 150 bn and is expected to grow at 10-14% CAGR over the coming five years.



Source: EvaluatePharma, Pareto.

Commercialisation of *Emcitate* & *Aladote*

Commercial infrastructure build up initiated

Strong success factors…

1. **High unmet medical need** without competing compounds
2. Centralized**, focused target** groups of **specialists**
3. **Top-down** scientific **sales approach**
4. **Leading KOL support**
5. Treatment algorithms **highly protocol driven**

…for sustainable, profitable & lean commercialisation

- Building **inhouse commercial capabilities** for launch of Emcitate® and Aladote® in EU and US
- **Small and focused footprint** with an estimated < 50 FTEs considered sufficient for both assets
- Retain **larger share of product revenues** over time within Company
- **Commercialisation** in other territories through **partners**

5.

Summary

Two highly promising orphan drug candidates

Emcitate® – *Therapy for genetic disturbance in thyroid hormone signaling with life-long severe disability*

- Lead candidate for addressing MCT8 deficiency which affects ~1:70,000 males, a condition with high unmet medical need and no available treatment. No competing sponsored products in clinical development
- Obtained Orphan drug designation in the EU and US 2017 and 2019, respectively. **US Rare Pediatric Disease Designation received in Nov 2020**, eligible for Priority Review Voucher. Fast track designation granted by FDA in Oct 2021
- Triac Trial I (Phase IIb) completed with **significant** and **clinically** relevant effects on **T3 levels** and the manifestations of **chronic thyrotoxicosis**
- Real-world data published in **Oct 2021 confirms long-term efficacy and safety** of Emcitate® in MCT8 deficiency patients
- Intend to **submit MAA** to EMA based on existing clinical data in **H1 2023**
- Intend to **NDA submission** in **mid 2023** based on treatment **effect on T3 levels** and the manifestations of **chronic thyrotoxicosis** in MCT8-deficiency. A placebo-controlled study in 16 treated patients will be conducted to verify the results on T3
- Triac Trial II fully recruited; to establish the effects of early intervention on neurocognitive development, previously seen in the Triac Trial I. Results are expected in Q1 2024
- More than 140 patients are being **treated** with Emcitate on a **named patient basis**, following individual regulatory approvals from the national regulatory agencies

Aladote® – *Prevents acute liver injury caused by paracetamol/acetaminophen poisoning*

- Paracetamol poisoning is one of the most common overdoses with >175,000 hospital admissions globally per annum
- No adequate treatment exists for increased risk patients
- Orphan drug designation (ODD) granted in 2019 in the US
- Ongoing dialogue with EMA on the appropriate scope of the indication for an ODD in the EU
- Successful results from Phase Ib/IIa study in paracetamol overdosed patients
- Pivotal Phase IIb/III study planned for marketing authorization application in both US and EU, targeting study start in 2022
- No competing products in clinical development

Late-stage orphan drug pipeline, $1Bn+ annual sales opportunity

Analogue benchmarks indicate substantial market potential

Emcitate®

Addressable patients[1]

> 10,000

Estimate of addressable patients globally with access to western standard health care[2]

Analogue pricing

> $250,000

Global average annual treatment cost per patient

Annual sales opportunity:

> $1Bn

If market penetration 50%

Aladote®

Target population

> 175,000

Estimate of addressable patients globally with access to western standard health care[2]

Pricing assumption

$5,000

Global average annual treatment cost per patient

Annual sales opportunity:

> $350mn

If market penetration 40%

COGS assumption: Low single digit percent

Source: (1) 1:70,000 males. Visser et al, Clinical Endocrinology 2012; (2) US, EU and RoW approachable population including Australia, Canada, Japan, Russia, Switzerland, South Korea and Turkey; Note: Royalties of 10% on Emcitate® net sales to Erasmus Medical Centre and Royalties of 3% on Emcitate® net sales to RTT owners

Upcoming pipeline milestones



*targeting study start 2022 pending the COVID-19 pandemic situation

An integrated orphan drug company, focusing on late-stage development for commercialization

1. Dedicated orphan drug development company with two late-stage orphan drug assets: **Emcitate®** and **Aladote®**
2. Target **MAA/NDA** submissions for **Emcitate** in **2023** and for **Aladote** in **2024/2025**
3. Highly attractive **orphan drug segment** with potential **>$1Bn annual sales opportunity**
4. Plan to **launch** through niche inhouse commercial organization in the EU and US
5. Combined core expertise in **late-stage orphan clinical development, registration and commercialization** with experience from:

Listed on NASDAQ Stockholm (EGTX)

HQ in Stockholm, Sweden

A.

Appendix

Leadership team

Nicklas Westerholm

CEO

- Took office in June 2017 and has previously worked in the AstraZeneca Group since 1995 in several global roles in various business areas, most recently as VP Project & Portfolio Management. Prior Nicklas has held positions such as Executive Officer & VP Japan Operations, Director Investor Relations, Head of Global API Supply and Head of Development Manufacture. He has studied Analytical and Organic Chemistry at Stockholm University and Chemical Engineering at KTH, as well as studies at University of Warwick, INSEAD and Harvard Business School.
- Ownership: 109,873 shares and 2,400,000 employee stock options

Yilmaz Mahshid

CFO

- Yilmaz has experience from different senior positions in the life science sector, including Investment Manager & Controller at Industrifonden, and CFO at PledPharma between 2017 and 2020, as well as healthcare analyst at Pareto Securities and Öhman Fondkommission. Prior to joining Egetis Therapeutics, Yilmaz was CEO of the listed biotech company Medivir. Yilmaz also has a solid academic background with a PhD from the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm.
- Ownership: 191,000 shares and 1,150,000 employee stock options

Henrik Krook

VP Commercial Operations

- Appointed VP Commercial Operations in December 2020. He has a broad experience from over 15 years in commercial leadership settings, including both big pharma and biotechs. He has previously held senior corporate and commercial advisory roles for biotech companies such as Affibody and senior managerial positions at e g Alexion, Novartis and Roche. Henrik has a PhD in immunology from Uppsala University and an Executive MBA from Stockholm School of Economics.
- Ownership: 170,000 shares and 1,150,000 employee stock options

Kristina Sjöblom Nygren

CMO

- Took office in May 2020 and has previously worked as CMO and Head of Development at Santhera, where she oversaw activities in late-stage clinical development, registration, post-approval commitments and managed access-programs within rare diseases in different therapeutic areas. Previously, Kristina spent 18 years at SOBI, Wyeth and AstraZeneca, where she held a number of senior positions. She has been involved in many different interactions with regulatory bodies such as the US FDA and the EMA including scientific advice and orphan drug applications. Before joining the industry, she worked as a licensed physician in several clinical positions. She holds a Diploma in Pharmaceutical Medicine, and an MD from the Karolinska Institute, Stockholm.
- Ownership: 6,000 shares and 650,000 employee stock options

Christian Sonesson

VP Product Strategy & Development

- Appointed VP Product Strategy & Development in August 2017 following 13 years at Astra Zeneca. He has broad experience within drug development, including successfully leading products during Phase 3 (FORXIGA® in type 1 diabetes) and of regulatory submissions and defense, bringing new drug candidates to market in different regions (e.g. FORXIGA® in type 2 diabetes, MOVANTIK®, ONGLYZA®-SAVOR, BRILINTA®-PEGASUS and QTERN®). PhD in Biostatistics from Gothenburg University and an Executive MBA from Stockholm School of Economics.
- Ownership: 12,000 shares and 1,150,000 employee stock options

Karl Hård

VP, Head of Investor Relations & Communications

- Appointed in February 2022. He has 25 years experience within the pharma and biotech sector, incl. 10 years in R&D and 9 years in Investor Relations at AstraZeneca, latterly as VP Investor Relations. Previously, Head of IR and Communications at Kiadis Pharma (The Netherlands) and Redx Pharma (UK). PhD in Bio-organic Chemistry from Utrecht University. Former Assistant Professor of Chemistry at Leiden University.
- Ownership: 0 shares and 100,000 employee stock options

Board of directors

Thomas Lönngren

Chairman of the board

- Board member since: 2021
- MSc in social and regulatory pharmacy and a degree in Pharmacy, University of Uppsala.
- Other assignments: Board member at Compass Pathsways PLC and NDA group. Director at own company PharmaExec Consulting AB. Advisor to NDA group, Artis Venture, Baren Therapeutics, Centre for Innovation in Regulatory Science (CIRS) and ScientificMed AB. Faculty member of GLG Institute
- Ownership: 165,219 shares

Mats Blom

Board member

- Board member since: 2021
- BA, Business Administration and Economics, University of Lund and MBA, IESE University of Navarra.
- Other assignments: CFO NorthSea Therapeutics and Board member of Hansa Biopharma and Auris Medical
- Ownership: 2,257,512 shares

Peder Walberg

Board member

- Founder and CEO of Rare Thyroid Therapeutics
- MD and BSc in international economy and business administration, Uppsala University
- Other assignments: Board Member of Immedica Pharma AB,
- Previous assignments: Founder and CEO, Medical Need, Head of Business Development and Strategy, Swedish Orphan International and SOBI. BoD of Wilson Therapeutics and identified Decuprate for treatment of Wilson disease
- Ownership: 31,858,414 shares (through Cetoros AB)

Gunilla Osswald

Board member

- Board member since: 2017
- Ph.D. in biopharmacy and pharmacokinetics
- Other assignments: CEO BioArctic AB
- Ownership: -

Elisabeth Svanberg

Board member

- Board member since: 2017
- MD, Ph.D., Assoc Professor in surgery
- Other assignments: Chief Development Officer Ixaltis SA. Chairman of the board Pharnext. Board member Swedish Orphan Biovitrum (SOBI), Amolyt Pharma and Galapagos
- Ownership: -

Share Register and Market Cap

Shareholders

Source: Monitor by Modular Finance. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority (Finansinspektionen). The verification date may vary for certain shareholders.

10 largest shareholders

Name	Capital	Votes	Num. of shares	Verified
Peder Walberg	19.30%	19.30%	31 858 414	2021-12-31
Peter Lindell	10.37%	10.37%	17 124 820	2021-12-31
Avla Holding AB	10.04%	10.04%	16 572 442	2021-12-31
Fjärde AP-fonden	8.67%	8.67%	14 311 300	2021-12-31
RegulaPharm AB	5.97%	5.97%	9 846 730	2021-12-31
Avanza Pension	2.67%	2.67%	4 406 802	2021-12-31
Thomas Eldered	1.79%	1.79%	2 953 462	2021-09-30
Carl Rosvall	1.64%	1.64%	2 707 914	2021-12-31
Mats Blom	1.37%	1.37%	2 257 512	2021-09-30
Unionen	1.28%	1.28%	2 120 165	2021-12-31
Total 10	**63.10%**	**63.10%**	**104 159 561**	
Total number of owners	6,895			2021-12-31
Total number of shares	165,068,560			2021-12-31

- Cash position: SEK 144M (~EUR 14M)*
- Number of outstanding shares: 165M
- MCap: ~SEK 940M**
- Listing venue: Nasdaq Stockholm Main Market

Source: Monitor by Modular Finance. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority (Finansinspektionen). The verification date may vary for certain shareholders
** At December 31, 2021 (Q4 2021 report); ** April 19, 2022*

Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million

Announced March 21, 2022

- To finance the preparations for regulatory submissions for market approval in EU and US, initiate the establishment of the Company's commercial infrastructure in Europe and US for Emcitate® and pre-launch activities, as well as general corporate purposes, in addition to providing financial flexibility
- Existing shareholders, including Cetoros AB (Peder W), Cidro Förvaltning AB (Peter L), Avla Holding AB (Kennet R), Fjärde AP-fonden, RegulaPharm AB (Gudrun H), Flerie Invest AB (Thomas E) and Unionen, as well as members of management and the Board of Directors, have undertaken to subscribe for shares representing approximately 39.3 percent of the Rights Issue
- The Company further strengthens its specialist investor base. New investors, including Linc AB, as well as existing shareholder Flerie Invest AB and members of management and the Board of Directors, have undertaken to subscribe for shares representing approximately 27.8 percent of the Rights Issue through assuming subscription rights of select existing shareholders free of cost
- In total, subscription undertakings represent approximately 67.2 percent of the Rights Issue, corresponding to approximately SEK 121.4 million.
- A consortium of existing shareholders, including Fjärde AP-fonden and members of management, as well as the new investor Linc AB, have undertaken to guarantee approximately 32.8 percent of the Rights Issue, corresponding to approximately SEK 59.4 million. Consequently, the Rights Issue is secured in its entirety.
- Approved at an extraordinary general meeting, on April 13, 2022

EGETIS THERAPEUTICS

Acquisition of Rare Thyroid Therapeutics on 5 November 2020

The combination will drive synergies

PledPharma and Rare Thyroid Therapeutics merged to launch a new company

PledPharma

- Team with profound late-stage drug development experience and strong track-record
- Listing on Nasdaq Stockholm provides access to public markets and capital as well as visibility
- Desired prospective partner in project collaborations. Previous major license agreement with Solasia
- Efficient internal organisation and strong corporate governance

Rare Thyroid Therapeutics

- Team with strong track-record of identifying and developing ODDs and creating shareholder value
- Strong network of external project advisors with specialist knowledge. Collaboration with Erasmus Medical Center in Rotterdam
- Founding team with experience from international launch and commercialisation of orphan drugs

Synergistic orphan drug focus

- 2020 accelerated PledPharma's strategic review
- Lead asset Aladote® facilitates the new pronounced strategic focus on orphan drug segment
- Emcitate® and RTT's capabilities fit well with the new strategy
- Build critical mass, generate synergies and improve operational effectiveness for projects in the orphan segment
- Size, vicinity and complementary capabilities allow for a fast and smooth integration

The acquisition and rights issue

Institutional investor base broadened

Acquisition

- On 5 November 2020, PledPharma acquired all outstanding common shares in Rare Thyroid Therapeutics
- Consideration consisted of a combination of PledPharma common shares and cash
  - An upfront cash payment of SEK 60m
  - 63.8 million shares representing approx 39% of the total number of outstanding shares in PledPharma post rights issues
  - Owners of Rare Thyroid Therapeutics will receive a royalty of 3% of net sales generated through Emcitate®[1]
  - Owners of Rare Thyroid Therapeutics will also be granted 50% of the net proceeds from a potential sale of US Rare Pediatric Disease Priority Review Voucher related to Emcitate®

Rights issue

- Successfully raised SEK 250 million in oversubscribed rights issue (c. SEK 200m) and utilized overallotment option (c. SEK 50m)
  - Subscription price of SEK 5.25 per share corresponding to a 2.5 percent premium to close 2 October 2020
- Institutional investor base broadened
  - Overallotment Option, allocated to the Fourth Swedish National Pension Fund ("AP4"), NYIP (Nyenburgh Holding BV) and Nordic Cross
- The proceeds will be used to finance: (i) the development of Emcitate® and Aladote® to market approval in Europe and USA (60%); (ii) initial commercial preparations (20%); (iii) general corporate purposes and financial flexibility (20%)

Note: (1) Royalties of 10% on Emcitate® net sales to Erasmus Medical Centre;

EGETIS THERAPEUTICS

Thank you!

Egetis Therapeutics
egetis.com